BD’s TriPath Imaging Buyout Would Integrate Cancer Diagnostics Partner
This article was originally published in The Gray Sheet
Executive Summary
Becton Dickinson will gain TriPath Imaging's SurePath liquid-based Pap test and fledgling molecular oncology diagnostics business should its $350 mil. acquisition offer be accepted